{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:41:20Z","timestamp":1761972080164,"version":"build-2065373602"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,10,30]]},"DOI":"10.1248\/bpb.b25-00199","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T22:06:26Z","timestamp":1761775586000},"page":"1634-1638","source":"Crossref","is-referenced-by-count":0,"title":["Multifactorial Alterations in Lacosamide Exposure in an Elderly Woman with Symptomatic Epilepsy and Tuberculous Pleurisy: A Case Report"],"prefix":"10.1248","volume":"48","author":[{"given":"Ryo","family":"Takeda","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, 1\u20135\u20131 Hiro-tagaya, Kure, Hiroshima 737\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, 1\u20135\u20131 Hiro-tagaya, Kure, Hiroshima 737\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Yokooji","sequence":"additional","affiliation":[{"name":"Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Oda","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5\u20131\u20131 Hirokoshinkai, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Takakura","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5\u20131\u20131 Hirokoshinkai, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5\u20131\u20131 Hirokoshinkai, Kure, Hiroshima 737\u20130112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Murakami","sequence":"additional","affiliation":[{"name":"Hiroshima International University, 555\u201336 Kurose Gakuendai, Higashi-Hiroshima, Hiroshima 739\u20132631, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Omoda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, 1\u20135\u20131 Hiro-tagaya, Kure, Hiroshima 737\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. <i>Epilepsy Res.<\/i>, <b>110<\/b>, 189\u2013205 (2015).","DOI":"10.1016\/j.eplepsyres.2014.11.021"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. <i>Clin. Pharmacokinet.<\/i>, <b>54<\/b>, 901\u2013914 (2015).","DOI":"10.1007\/s40262-015-0276-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent <i>antiepileptic drugs<\/i>. <i>Drugs R D.<\/i>, <b>16<\/b>, 303\u2013316 (2016).","DOI":"10.1007\/s40268-016-0148-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Zhao T, Li HJ, Zhang HL, Yu J, Feng J, Cui L, Sun KF, Sun Y, Yu LH. Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China. <i>Eur. J. Pediatr.<\/i>, <b>184<\/b>, 73 (2024).","DOI":"10.1007\/s00431-024-05897-6"},{"key":"5","unstructured":"5) Li Y, Guo HL, Wang J, Zhang YY, Wang WJ, Huang J, Fan L, Hu YH, Lu XP, Chen F. <i>CYP2C19<\/i> genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical response. <i>Ther. Adv. Neurol. Disord.<\/i>, <b>17<\/b>, 17562864241273087 (2024)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Cawello W, Stockis A, Andreas JO, Dimova S. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>1329<\/b>, 18\u201332 (2014).","DOI":"10.1111\/nyas.12513"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ahn SJ, Oh J, Kim DY, Son H, Hwang S, Shin HR, Kim EY, Lee HS, Lee WJ, Moon J, Lee ST, Jung KH, Park KI, Jung KY, Lee S, Yu KS, Chu K, Lee SK. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. <i>Epilepsia<\/i>, <b>63<\/b>, 2958\u20132969 (2022).","DOI":"10.1111\/epi.17399"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamamoto Y, Shiratani Y, Nishida T, Usui N, Kagawa Y, Takahashi Y, Imai K. Lacosamide pharmacokinetics and retention in Japanese patients with epilepsy: a retrospective study on the influence of age, comedications, and cytochrome P450 2C19 polymorphism. <i>Ther. Drug Monit.<\/i>, <b>47<\/b>, 407\u2013412 (2025).","DOI":"10.1097\/FTD.0000000000001278"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, Namiki N, Odagiri K, Watanabe H. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. <i>J. Pharmacol. Sci.<\/i>, <b>139<\/b>, 361\u2013366 (2019).","DOI":"10.1016\/j.jphs.2019.03.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) J\u00e4rvinen E, Hammer HS, P\u00f6tz O, Ingelman-Sundberg M, Stage TB. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. <i>Clin. Pharmacol. Ther.<\/i>, <b>113<\/b>, 1284\u20131294 (2023).","DOI":"10.1002\/cpt.2887"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>302<\/b>, 475\u2013482 (2002).","DOI":"10.1124\/jpet.102.033837"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. <i>Drug Metab. Dispos.<\/i>, <b>31<\/b>, 282\u2013288 (2003).","DOI":"10.1124\/dmd.31.3.282"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kanebratt KP, Diczfalusy U, B\u00e4ckstr\u00f6m T, Sparve E, Bredberg E, B\u00f6ttiger Y, Andersson TB, Bertilsson L. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. <i>Clin. Pharmacol. Ther.<\/i>, <b>84<\/b>, 589\u2013594 (2008).","DOI":"10.1038\/clpt.2008.132"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Stemkens R, Jager V, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. <i>Antimicrob. Agents Chemother.<\/i>, <b>67<\/b>, e0068323 (2023).","DOI":"10.1128\/aac.00683-23"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shah S, Vasantharaju SG, Arumugam K, Muddukrishna BS, Desai N. Development of a sensitive bioanalytical method for the quantification of lacosamide in rat plasma. Application to preclinical pharmacokinetics studies in rats. <i>Arzneimittelforschung<\/i>, <b>62<\/b>, 243\u2013246 (2012).","DOI":"10.1055\/s-0032-1301911"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wong SG, Ramsden D, Dallas S, Fung C, Einolf HJ, Palamanda J, Chen L, Goosen TC, Siu YA, Zhang G, Tweedie D, Hariparsad N, Jones B, Yates PD. Considerations from the Innovation and Quality Induction Working Group in response to Drug-Drug Interaction Guidance from regulatory agencies: guidelines on model fitting and recommendations on time course for <i>in vitro<\/i> cytochrome P450 induction studies including impact on drug interaction risk assessment. <i>Drug Metab. Dispos.<\/i>, <b>49<\/b>, 94\u2013110 (2021).","DOI":"10.1124\/dmd.120.000055"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. Determination of CYP450 expression levels in the human small intestine by mass spectrometry-based targeted proteomics. <i>Int. J. Mol. Sci.<\/i>, <b>22<\/b>, 12791 (2021).","DOI":"10.3390\/ijms222312791"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Yamamoto Y, Terada K, Araki Y, Fukushima Y, Imai K, Kagawa Y, Takahashi Y. Therapeutic monitoring of lacosamide in Japanese patients with epilepsy: clinical response, tolerability, and optimal therapeutic range. <i>Ther. Drug Monit.<\/i>, <b>42<\/b>, 754\u2013759 (2020).","DOI":"10.1097\/FTD.0000000000000764"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Guo M, Dai X, Hu D, Zhang Y, Sun Y, Ren W, Wang L. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: roles of P-glycoprotein and BCRP induction by rifampicin. <i>Poult. Sci.<\/i>, <b>95<\/b>, 2129\u20132135 (2016).","DOI":"10.3382\/ps\/pew148"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Zhang C, Chanteux H, Zuo Z, Kwan P, Baum L. Potential role for human P-glycoprotein in the transport of lacosamide. <i>Epilepsia<\/i>, <b>54<\/b>, 1154\u20131160 (2013).","DOI":"10.1111\/epi.12158"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. <i>Biol. Pharm. Bull.<\/i>, <b>29<\/b>, 779\u2013784 (2006).","DOI":"10.1248\/bpb.29.779"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>1<\/b>, 629\u2013640 (2005).","DOI":"10.1517\/17425255.1.4.629"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>57<\/b>, 799\u2013804 (2002).","DOI":"10.1007\/s00228-001-0396-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. <i>J. Pharmacol. Sci.<\/i>, <b>96<\/b>, 293\u2013300 (2004).","DOI":"10.1254\/jphs.FP0040296"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Shimokawa Y, Yoda N, Kondo S, Yamamura Y, Takiguchi Y, Umehara K. Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 1425\u20131429 (2015).","DOI":"10.1248\/bpb.b15-00313"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lee SY, Jang H, Lee JY, Kwon KI, Oh SJ, Kim SK. Inhibition of cytochrome P450 by ethambutol in human liver microsomes. <i>Toxicol. Lett.<\/i>, <b>229<\/b>, 33\u201340 (2014).","DOI":"10.1016\/j.toxlet.2014.06.006"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00199\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:24:15Z","timestamp":1761967455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00199\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00199","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"b25-00199"}}